Article

The size of mediastinal lymph nodes and its relation with metastatic involvement: a meta-analysis.

Department of Nuclear Medicine and PET Research, VU University Medical Center, De Boelelaan 1117, 1081HV Amsterdam, The Netherlands.
European Journal of Cardio-Thoracic Surgery (Impact Factor: 2.67). 02/2006; 29(1):26-9. DOI: 10.1016/j.ejcts.2005.10.002
Source: PubMed

ABSTRACT Positron emission tomography with 18-fluorodeoxyglucose (FDG-PET) seems to be superior to computed tomography (CT) in staging the mediastinum in patients with non-small-cell lung cancer (NSCLC). However, recent results suggest that FDG-PET performance characteristics are conditional for nodal size as shown by CT: FDG-PET is more sensitive but less specific with lymph node enlargement on CT. The association between size and the probability of malignancy needs to be known to predict the post-test probabilities after PET, and finally, stratify patients for mediastinoscopy or thoracotomy depending on the PET and CT results. Therefore, we performed a meta-analysis of available studies reporting on the prevalence of metastatic involvement for different size categories of enlarged lymph nodes in patients with NSCLC and were able to include 14 studies. The prevalence of metastatic involvement and conditional test performance of CT and FDG-PET were calculated for lymph nodes measuring 10-15 mm, 16-20 mm and >20 mm. We found a post-test probability for N2 disease of 5% for lymph nodes measuring 10-15 mm on CT in patients with a negative FDG-PET result, suggesting that these patients should be planned for thoracotomy because the yield of mediastinoscopy will be extremely low. For patients with lymph nodes measuring > or =16 mm on CT and a negative FDG-PET result a post-test probability for N2 disease of 21% was found, suggesting that these patients should be planned for mediastinoscopy prior to possible thoracotomy to prevent too many unnecessary thoracotomies in this subset.

0 Bookmarks
 · 
95 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the efficacy of (18)F-FDG PET/CT in depicting metastatic mediastinal lymph nodes in patients with lung squamous-cell carcinoma (LSCC) or lung adenocarcinoma (LAC) in a tuberculosis-endemic country. This study retrospectively reviewed patients with LSCC or LAC, who underwent preoperative (18)F-FDG PET/CT to assess mediastinal lymph node metastasis. Patients with the short-axis of mediastinal lymph node≤15mm were included. PET/CT interpretation was analyzed in two ways. Firstly, with CT for anatomical localization, lymph nodes showing greater (18)F-FDG uptake than vessel pool on PET were regarded malignant. Secondly, lymph nodes with positive uptake on PET were considered malignant, only when nodes had neither calcification nor higher attenuation than vessel pool on CT. One hundred and sixteen LSCCs and 234 LACs were evaluated. With CT for anatomical localization, the sensitivity, specificity, accuracy, positive predictive value (PPV) and negative predictive value (NPV) of PET were 78.6%, 45.5%, 53.4%, 31.4% and 87.0% in LSCC group, and 61.8%, 66.3%, 65.0%, 42.9% and 80.9% in LAC group. PET showed higher specificity and accuracy in LAC group compared with LSCC group (p=0.001 and p=0.038, respectively). Considering calcification or high attenuation on CT, the sensitivity, specificity, accuracy, PPV and NPV of PET/CT were 71.4%, 67.0%, 68.1%, 40.8% and 88.1% in LSCC group, and 54.4%, 86.1%, 76.9%, 61.7% and 82.2% in LAC group. Compared with PET, PET/CT possessed higher specificity and accuracy in LSCC group (p=0.000 and p=0.000, respectively), and higher specificity, accuracy and PPV in LAC group (p=0.000, p=0.000 and p=0.022, respectively). (18)F-FDG PET displays limited efficacy in assessing mediastinal lymph node metastasis with the short-axis diameter <15mm in LSCC and LAC groups and higher false-positivity in LSCC group. The specificity and accuracy in LSCC and LAC groups are enhanced by interpreting attenuation characteristic on CT.
    Lung cancer (Amsterdam, Netherlands) 04/2014; · 3.14 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Disease stage is the most important prognostic factor in lung cancer, and optimal staging is important to determine the best therapeutic option. FDG-PET/CT has demonstrated its value in early stage non-small cell lung cancer (NSCLC) but there is still insufficient data to define its role in other stages. Information provided by FDG-PET/CT has an impact on the therapeutic management of patients with NSCLC. A retrospective review was made of patients who underwent FDG-PET/CT between January 2008 and December 2010 for the diagnosis of NSCLC. Clinical stage before and after FDG-PET/CT and information about any change in therapeutic decision due to information provided by FDG-PET/CT were collected. Using pathologic evaluation as the gold standard, sensitivity, specificity, and positive and negative predictive values for CT and FDG-PET/CT were calculated. Of the 522 patients diagnosed of NSCLC, FDG-PET/CT was performed in 246 (47.1%). In 85 cases (34.6%) FDG-PET/CT led to stage migration. Treatment was modified in 60 patients (24.4% of all FDG-PET/CT performed), avoiding a futile thoracotomy in 13 cases (5.2%), and allowing treatment with curative intent in 26 (10.5%). Out of 90 patients (36.5%) evaluated as stage iii by CT staging, FDG-PET/CT modified the therapeutic approach in 36 (40%). For the 133 cases (54%) with pathological assessment of the mediastinal lymph nodes, sensitivity, specificity, positive predictive value and negative predictive value were 0.57, 0.64, 0.48 and 0.72 for CT, and 0.68, 0.86, 0.75 and 0.81 for FDG-PET/CT. Our data support previous reports that FDG-PET/CT is essential in the staging process not only for patients with potentially operable NSCLC but also for stage iii patients, as demonstrated by our data.
    Archivos de Bronconeumología 12/2013; · 2.17 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Since there is high local failure and poor survival for unresectable esophageal squamous cell carcinoma (ESCC), the necessity of elective node irradiation is controversial. The purpose of this study was to investigate the failure patterns and survival in patients with locally advanced ESCC receiving involved-field irradiation (IFI). A retrospective study was preformed on the clinical records of patients with locally advanced ESCC, who have received IFI with concurrent chemotherapy between January 2003 and January 2009. Comparing the target volume and first sites of failure, patterns of failure were defined as in-field, out-of-field regional lymph node and distant failure. The survivals were analyzed by different patterns of failure. Eighty patients were included in our study. With a median follow-up of 52.6 months, failures were observed in 76 patients. In-field recurrence, distant metastasis, and out-of-field regional failure were seen in 53.75%, 41.25%, 30% patients, respectively. There were significant differences in OS for patients with and without in-field (median OS 14.2 vs.17.4 m, P = 0.01)or distant failure(13.2 vs.15.9 m, P <= 0.0001), but not for out-of-field regional lymph node failure(both 14.5 m, P = 0.665). The solitary regional nodal failure of out-of-field was acceptable in advanced ESCC patients treated with IFI. In-field and distant failures remained the predominant patterns and negatively impacted survival more significantly. Further investigation is needed to establish the optimal radiotherapy field for these patients at advanced stage.
    Radiation Oncology 02/2014; 9(1):64. · 2.11 Impact Factor

Full-text (2 Sources)

View
42 Downloads
Available from
May 22, 2014